Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

oximately 5,000 to 8,000 Canadians.
Up to six months are needed to secure coverage for new medicines from the major private insurance companies in Canada and, on average, about 18 months are needed to secure reimbursement for all 10 provincial governments that reimburse the majority of medicines in Canada.
  • At the end of 2012, InterMune had concluded successful pricing and reimbursement discussions in nine European countries: Austria, Belgium, Denmark, France, Germany, Iceland, Luxembourg, Norway and Sweden.
  • InterMune today reiterated its current expectations regarding the on-going pricing and reimbursement processes for Esbriet in other European countries, processes over which InterMune has no control:
  • The UK – The appraisal by the National Institute for Health and Clinical Excellence (NICE) is expected to be completed in March of 2013.  If NICE provides a positive appraisal for Esbriet and the pricing and reimbursement conditions are acceptable, the company expects to launch Esbriet as soon as possible thereafter.
  • Italy – The company continues to expect to conclude the pricing and reimbursement process in the first quarter of 2013 and to launch Esbriet in Italy as soon as possible after the process is successfully concluded, assuming that acceptable pricing and reimbursement conditions are negotiated.  In Italy, up to three quarters are needed after national pricing and reimbursement is secured to address all regional reimbursement procedures before complete patient access to Esbriet is achieved.
  • Spain – InterMune currently expects to conclude pricing and reimbursement of Esbriet in Spain by mid-2013 and to launch as soon as possible after pricing and reimbursement is concluded, assuming that acceptable pricing and reimbursement conditions are negotiated.  In Spain, up to four quarters are needed after national reimbursement is secured to address all regional reimbursement proced
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
    (Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
    (Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
    (Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
    Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
    ... Dec. 9 BioMarin Pharmaceutical,Inc. (Nasdaq: ... partner Merck Serono, a division,of Merck KGaA, ... (sapropterin dihydrochloride) for the treatment of,hyperphenylalaninemia (HPA) ... the European Commission. Merck Serono estimates ...
    ... DCTH ) today announced the appointment of Roger G. ... Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: COR ), ... disorders. , , (Logo: ... Prior to joining Cortex, Dr. Stoll worked as a consultant ...
    ... Md., Dec. 9 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,announced ... of ENMD-2076 in refractory,multiple myeloma patients. The study ... Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. ...
    Cached Biology Technology:Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 2EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 4
    (Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
    (Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
    (Date:8/20/2014)... Health has awarded the Oklahoma Medical Research Foundation a ... anthrax and the bacteria,s effects on humans. , ... his colleagues have studied the human immune response to ... Human Immunology. The original funding came soon after anthrax-laced ... of the terrorist attacks of Sept. 11, 2001. ...
    Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2$14.5 million grant awarded to continue anthrax studies 2
    ... Rome, Italy: Researchers have developed a way of accurately ... blood test. The average difference between the predicted age and ... the menopause was only a third of a year, and ... years. Dr Fahimeh Ramezani Tehrani will tell the 26th ...
    ... new technology that allows scientists to monitor how individual cells ... researchers have uncovered a much larger spectrum of differences between ... act in a uniform fashion, as was previously thought. ... Markus Covert, PhD, assistant professor of bioengineering and senior author ...
    ... 27th, 2010 The Elsevier Foundation, TWAS and TWOWS ... scientists from Africa, the Middle East, Asia, Latin America ... was made at the Third World Organization for Women ... Women Scientists in a Changing World, hosted by the ...
    Cached Biology News:Researchers develop accurate way to predict the age when women will hit the menopause 2Researchers develop accurate way to predict the age when women will hit the menopause 3Same types of cell respond differently to stimulus, Stanford study shows 2Same types of cell respond differently to stimulus, Stanford study shows 312 women scientists announced as winners of Elsevier Foundation TWOWS Awards 2
    ... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and Silencer Pre-designed ...
    , Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
    , Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
    Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
    Biology Products: